Ovid Therapeutics Inc. (Ovídio): Modelo de Negócios Canvas [Jan-2025 Atualizado]

Mergulhe no mundo inovador da Ovid Therapeutics Inc., uma empresa inovadora de biotecnologia que revoluciona o tratamento de doenças neurológicas por meio de sua tela estratégica de modelo de negócios. Com uma abordagem focada em laser em distúrbios neurológicos raros, Ovídio está transformando a pesquisa médica, combinando neurociência de ponta, medicina de precisão e estratégias de desenvolvimento de medicamentos centradas no paciente. Seu modelo exclusivo preenche a inovação científica com soluções terapêuticas, promissor esperança para os pacientes que enfrentam desafios neurológicos complexos e potencialmente remodelando o cenário de intervenções médicas direcionadas.

OVID Therapeutics Inc. (Ovídio) - Modelo de Negócios: Principais Parcerias

Colaborações estratégicas com instituições de pesquisa acadêmica

Instituição	Foco na pesquisa	Ano de parceria
Hospital Geral de Massachusetts	Distúrbios neurológicos raros	2022
Universidade da Pensilvânia	Pesquisa de epilepsia genética	2021

Parcerias de desenvolvimento farmacêutico

Principais colaborações de desenvolvimento:

• Takeda Pharmaceutical Company Limited - Programas de doenças neurológicas raras
• Lundbeck A/S - Desenvolvimento de medicamentos para transtorno neurológico

Acordos de licenciamento com empresas de biotecnologia

Empresa de biotecnologia	Detalhes do contrato de licenciamento	Valor
Biosciências xenéticas	Plataforma terapêutica de doenças raras	Pagamento inicial de US $ 3,2 milhões

Agências regulatórias para processos de aprovação de medicamentos

• Administração de Alimentos e Medicamentos dos EUA (FDA)
• Agência Europeia de Medicamentos (EMA)

Redes de pesquisa de ensaios clínicos

Rede	Área de foco	Ensaios ativos
Consórcio enigma	Pesquisa de epilepsia genética	4 ensaios clínicos em andamento
Rede de epilepsia rara	Distúrbios neurológicos raros	3 colaborações de pesquisa ativa

Ovid Therapeutics Inc. (Ovídio) - Modelo de Negócios: Atividades -chave

Desenvolvimento de medicamentos para doenças neurológicas raras

A partir do quarto trimestre 2023, a terapêutica ovídica se concentrava no desenvolvimento de terapias para distúrbios neurológicos raros com 3 candidatos a drogas primárias.

Candidato a drogas	Transtorno alvo	Estágio de desenvolvimento
OV101	Síndrome de Angelman	Fase 2/3 Ensaios Clínicos
OV935	Epilepsias pediátricas raras	Ensaios clínicos de fase 2

Pesquisa pré -clínica e clínica

O ovídio terapêutica investiu US $ 24,3 milhões em despesas de P&D Para o ano fiscal de 2023.

• Mantido 12 programas de pesquisa ativos
• Conduzido 2 ensaios clínicos em andamento
• Colaborou com 3 instituições de pesquisa

Inovação terapêutica da neurociência

Especializado no desenvolvimento de novas terapêuticas de neurociência com Concentre -se em distúrbios genéticos.

Área de inovação	Foco na pesquisa
Terapias genéticas	Distúrbios neurológicos raros
Direcionamento molecular	Abordagem de medicina de precisão

Submissão e conformidade regulatórios

Enviado 2 Aplicações de novos medicamentos para investigação (IND) para FDA em 2023.

• Mantido conformidade com os regulamentos da FDA
• Envolvido em comunicação regulatória contínua

Pesquisa em Medicina Translacional

Alocado 37% do orçamento de pesquisa para iniciativas de medicina translacional.

Área de pesquisa	Alocação de orçamento
Estudos pré -clínicos	US $ 8,7 milhões
Desenvolvimento de Biomarcadores	US $ 5,2 milhões

Ovid Therapeutics Inc. (Ovídio) - Modelo de Negócios: Recursos -Principais

Equipe especializada de pesquisa de neurociência

A partir do quarto trimestre 2023, a Ovid Therapeutics empregou 52 pessoal de pesquisa e desenvolvimento.

Categoria de pessoal	Número de funcionários
Pesquisadores de doutorado	23
Cientistas clínicos	15
Associados de pesquisa	14

Plataformas proprietárias de desenvolvimento de medicamentos

Ovídio Therapeutics desenvolveu 2 plataformas de desenvolvimento de medicamentos primários focado em distúrbios neurológicos raros.

• Plataforma de terapia genética direcionada a síndromes raras de epilepsia
• Plataforma de intervenção neurológica de pequenas moléculas

Portfólio de propriedade intelectual

Em dezembro de 2023, o Ovídio Therapeutics mantinha:

Tipo IP	Contagem total
Patentes ativas	14
Aplicações de patentes	8

Laboratórios de Pesquisa Avançada

O Ovídio Therapeutics opera 1 Instalação de Pesquisa Primária Localizado em Boston, Massachusetts, abrangendo 12.500 pés quadrados.

Infraestrutura do ensaio clínico

Portfólio atual de ensaios clínicos a partir de 2024:

Fase de teste	Número de ensaios ativos
Fase I.	2
Fase II	3
Fase III	1

Ovid Therapeutics Inc. (Ovídio) - Modelo de Negócios: Proposições de Valor

Tratamentos inovadores para distúrbios neurológicos raros

O Ovídio Therapeutics se concentra no desenvolvimento de terapias para distúrbios neurológicos raros, com ênfase específica nas seguintes áreas -chave:

Transtorno	Estágio de desenvolvimento	População alvo de pacientes
Síndrome de Angelman	Ensaio clínico de fase 2	Aproximadamente 1 em 12.000 a 20.000 indivíduos
Síndrome X frágil	Pesquisa pré -clínica	Estimado 1 em 4.000 homens

Soluções terapêuticas direcionadas para necessidades médicas não atendidas

O Ovídio Therapeutics da Pipeline tem como alvo condições neurológicas específicas com opções de tratamento existentes limitadas:

• Distúrbios neurológicos genéticos raros
• Condições do desenvolvimento neurológico
• Síndromes relacionadas à epilepsia

Abordagem de medicina de precisão em neurociência

Estratégia de segmentação genética:

Plataforma de tecnologia	Abordagem genética	Investimento em pesquisa
Modulação do receptor GABA	Direcionamento genético de precisão	US $ 14,2 milhões em despesas de P&D (2023)

Terapias potenciais inovadoras para condições neurológicas

Candidatos terapêuticos -chave no desenvolvimento:

• OV101 (GABOXADOL) para a síndrome de Angelman
• Tak-935 para encefalopatias de desenvolvimento e epiléptico
• Plataformas de intervenção genética de precisão

Estratégias de desenvolvimento de medicamentos focados no paciente

Métricas de desenvolvimento clínico:

Métrica	Valor
Total de programas clínicos	3 programas ativos
Capacidade de inscrição do paciente	Aproximadamente 200 pacientes entre os ensaios
Orçamento anual de pesquisa clínica	US $ 22,5 milhões

Ovid Therapeutics Inc. (Ovídio) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com grupos de defesa do paciente

A partir de 2024, a Ovid Therapeutics mantém parcerias estratégicas com 7 organizações de defesa de pacientes com transtorno neurológico raro.

Grupo de pacientes	Foco de colaboração	Frequência de interação anual
Aliança CDKL5	Suporte de pesquisa	12 eventos de engajamento
Fundação da Síndrome de Dravet	Consciência do ensaio clínico	8 programas colaborativos

Consulta profissional médica e educação

O Ovídio Therapeutics realiza 45 seminários educacionais profissionais médicos anualmente, visando neurologistas e especialistas em epilepsia.

• Programas de treinamento credenciados por CME: 18
• Participação da conferência virtual: 27 eventos
• Diretor de neurologista direto: 326 especialistas

Programas personalizados de apoio ao paciente

A empresa opera uma infraestrutura dedicada de suporte ao paciente com 22 coordenadores de cuidados especializados.

Serviço de suporte	Alcance anual	Tempo de resposta
Helpline do paciente	1.247 pacientes	Resposta de 24 horas
Assistência financeira	387 aplicações de pacientes	Processamento de 5 dias

Comunicação transparente sobre desenvolvimentos clínicos

O Ovid Therapeutics publica 14 atualizações de desenvolvimento clínico anualmente em vários canais de comunicação.

• Comunicados de imprensa: 6 por ano
• Apresentações da Conferência de Investidores: 4 por ano
• Publicações de revistas científicas: 4 por ano

Colaboração de pesquisa em andamento com a comunidade médica

A empresa mantém colaborações ativas de pesquisa com 12 centros médicos acadêmicos.

Instituição de pesquisa	Tipo de colaboração	Investimento anual
Universidade Johns Hopkins	Pesquisa CDKL5	$875,000
Departamento de Neurologia de Stanford	Estudo do mecanismo de epilepsia	$650,000

Ovid Therapeutics Inc. (Ovídio) - Modelo de Negócios: Canais

Equipe direta de vendas médicas

A partir do quarto trimestre de 2023, a Ovid Therapeutics mantém uma força de vendas especializada de 12 profissionais direcionados aos centros de tratamento neurológico e especialistas em doenças raras.

Métrica da equipe de vendas	2023 dados
Total de representantes de vendas	12
Cobertura geográfica	Estados Unidos
Áreas de foco especializadas	Distúrbios neurológicos raros

Centros de tratamento neurológico especializados

O Ovídio Therapeutics colabora com 47 centros de tratamento neurológico especializados nos Estados Unidos.

• Os 5 principais centros: Mayo Clinic, Johns Hopkins, Cleveland Clinic, Hospital Geral de Massachusetts, UCSF Medical Center
• Foco primário: epilepsia rara e distúrbios neurológicos genéticos

Plataformas de saúde digital

Os canais de engajamento digital incluem 3 plataformas on -line primárias com 8.752 profissionais de saúde registrados em dezembro de 2023.

Plataforma digital	Usuários registrados
OvidConnect	4,213
Rede neuroprofissional	3,245
Portal digital de doenças raras	1,294

Conferências médicas e simpósios

O Ovídio Therapeutics participou de 22 conferências médicas em 2023, com engajamento direto de 673 profissionais médicos.

• Conferências -chave: Reunião Anual da American Epilepsy Society
• Conferência da Sociedade de Neurologia Infantil
• Simpósio Internacional de Pesquisa de Doenças Raras

Redes de publicação de pesquisa on -line

A empresa mantém a presença em 6 principais redes de publicação de pesquisa com 215 documentos de pesquisa publicados a partir de 2023.

Rede de pesquisa	Pesquisa publicada
PubMed	87
Pesquisa	62
Google Scholar	66

Ovid Therapeutics Inc. (Ovídio) - Modelo de Negócios: Segmentos de Clientes

Pacientes com transtorno neurológico

Tamanho do mercado para distúrbios neurológicos raros: 25-30 milhões de pacientes nos Estados Unidos

Tipo de distúrbio	População estimada de pacientes
Síndromes raras de epilepsia	500.000 pacientes
Síndrome de Angelman	Aproximadamente 15.000 pacientes

Especialistas em neurologia pediátrica

Número de neurologistas pediátricos nos Estados Unidos: 1.400 especialistas certificados pelo conselho

• Consultas médias anuais dos pacientes: 750-1.000 por especialista
• Concentração em centros médicos acadêmicos: 60% dos especialistas

Centros de pesquisa de doenças raras

Número total de centros dedicados de pesquisa de doenças raras nos EUA: 87

Tipo de centro de pesquisa	Número de centros
Centros Médicos Acadêmicos	53
Institutos de pesquisa independentes	34

Provedores de saúde

Total de Instalações de Cuidados Neurológicos nos Estados Unidos: 2.300

• Clínicas de neurologia especializadas: 680
• Centros abrangentes de epilepsia: 139

Organizações de defesa de pacientes

Número de raros grupos de defesa de pacientes com transtorno neurológico: 215

Foco de advocacia	Número de organizações
Grupos de apoio à epilepsia	87
Redes de transtorno genético raras	128

Ovid Therapeutics Inc. (Ovídio) - Modelo de Negócios: Estrutura de Custo

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2022, a Ovid Therapeutics registrou despesas totais de P&D de US $ 36,4 milhões.

Ano	Despesas de P&D
2022	US $ 36,4 milhões
2021	US $ 44,5 milhões

Investimentos de ensaios clínicos

Os custos de ensaios clínicos da Ovídia Therapeutics em 2022 foram de aproximadamente US $ 24,7 milhões.

• Foco primário em distúrbios neurológicos raros
• Ensaios em andamento para epilepsia e condições genéticas raras

Custos de conformidade regulatória

As despesas de conformidade regulatória de 2022 totalizaram aproximadamente US $ 3,2 milhões.

Aquisição de pessoal e talento

Ano	Compensação total dos funcionários
2022	US $ 18,6 milhões
2021	US $ 22,1 milhões

Manutenção de propriedades patentes e intelectuais

Os custos anuais de manutenção da propriedade intelectual foram de aproximadamente US $ 1,5 milhão em 2022.

• Custos operacionais totais para 2022: US $ 84,4 milhões
• Redução nas despesas gerais em comparação com o ano anterior

Ovid Therapeutics Inc. (Ovídio) - Modelo de Negócios: Fluxos de Receita

Acordos potenciais de licenciamento de medicamentos

A partir de 2023, a Ovid Therapeutics não relatou nenhum acordos ativos de licenciamento de medicamentos que geram receita significativa.

Vendas futuras de produtos farmacêuticos

O Ovídio Therapeutics registrou receita total de US $ 11,4 milhões para o ano fiscal de 2022, principalmente de colaborações de pesquisa e desenvolvimento.

Candidato a produto	Área terapêutica	Estágio de desenvolvimento	Valor potencial de mercado
OV101	Síndrome de Angelman	Estágio clínico	Estimado US $ 250-500 milhões
OV935	Epilepsias raras	Pré -clínico	Estimado US $ 150-300 milhões

Bolsas de pesquisa e financiamento

Em 2022, Ovídio recebeu financiamento de pesquisas e subsídios totalizando aproximadamente US $ 3,2 milhões.

Parcerias de pesquisa colaborativa

• Parceria com a Takeda Pharmaceutical para programas de epilepsia raros
• Colaboração com a Fundação CHDI para a pesquisa de doenças de Huntington

Potenciais pagamentos marcantes do desenvolvimento de medicamentos

Os pagamentos em potencial de parcerias existentes podem variar entre US $ 10 a 50 milhões com base no progresso do desenvolvimento.

Parceiro	Potenciais pagamentos marcantes	Condições
Takeda Pharmaceutical	Até US $ 25 milhões	Achedas de desenvolvimento clínico
Fundação CHDI	Até US $ 15 milhões	Pesquisa Progressão Marco

Ovid Therapeutics Inc. (OVID) - Canvas Business Model: Value Propositions

You're looking at the core value Ovid Therapeutics Inc. (OVID) is trying to deliver to patients and the healthcare system as of late 2025. It's all about creating differentiated, first-in-class, or best-in-class small molecule medicines for serious brain conditions where the current options just aren't cutting it.

The value propositions center on two distinct, novel mechanisms of action, both aimed at restoring the proper balance of excitation and inhibition in the brain.

Next-generation GABA-AT inhibitor (OV329) with a differentiated safety profile

The value here is offering a potential successor to older therapies for conditions like drug-resistant epilepsies (DREs). OV329 is a next-generation GABA-aminotransferase (GABA-AT) inhibitor, designed to increase GABA, the brain's main inhibitory neurotransmitter.

The differentiation comes from its potency and safety profile compared to vigabatrin (VGB), a first-generation GABA-AT inhibitor:

• - Preclinical data suggested OV329 is 100- to 1,000-fold more potent than vigabatrin in animal models.
• - The Phase 1 study in healthy volunteers, with topline results reported in Q3 2025, confirmed strong inhibitory activity.
• - OV329 matched or exceeded inhibition demonstrated by therapeutic doses of vigabatrin, as measured on transcranial magnetic stimulation (TMS).
• - The design aims to avoid the serious safety concerns associated with VGB, such as irreversible vision loss.

This proposition targets a significant unmet need, as as many as one in three patients with DREs do not respond to current medications. Ovid Therapeutics Inc. is planning to advance OV329 into a Phase 2a study in adult patients with drug-resistant focal onset seizures, planned to initiate in Q2 2026.

First-in-class KCC2 direct activators (OV350/OV4071) targeting neural hyperexcitability

This represents a truly novel approach: directly activating the potassium-chloride cotransporter 2 (KCC2) to restore the brain's natural inhibitory brake. This mechanism has potential across multiple neurological and neuropsychiatric disorders driven by excess neuronal excitation.

The pipeline includes two key candidates:

Candidate	Formulation/Status (Late 2025)	Key Milestone Expected
OV350	Intravenous (IV) formulation; Dosing initiated in healthy volunteers in Q1 2025.	Safety, tolerability, and pharmacokinetic data anticipated in Q4 2025.
OV4071	Oral formulation; Completing IND-enabling activities.	Plan to submit for regulatory clearance in Q1 2026; Phase 1/1b study start in Q2 2026.

The value is establishing the foundational safety for this new class of medicines, with OV350 data informing the development of the oral candidates like OV4071.

Precision medicine approach for brain conditions with high unmet need

Ovid Therapeutics Inc. focuses its development efforts where existing treatments are inadequate, which is a core value driver for payers and prescribers. The company's strategy is grounded in understanding the underlying biology of these disorders.

The commitment to this approach is supported by the financial structure in place to see these programs through critical milestones:

• - Following an initial closing of approximately $81 million in October 2025, the total capital raised from a private placement of up to $175 million is expected to extend the cash runway into 2H 2028.
• - The company also generated $7.0 million in June 2025 from a royalty monetization agreement for ganaxolone, providing non-dilutive capital.
• - Cash, cash equivalents, and marketable securities as of September 30, 2025, totaled $25.6 million.

These resources are intended to support the pipeline through key data readouts, such as the OV329 Q3 2025 results and the OV350 Q4 2025 data.

Potential oral treatment (OV4071) for neuropsychiatric disorders like Parkinson's psychosis

The value proposition for OV4071 is its potential as the first oral KCC2 direct activator, offering a convenient dosing form for chronic neuropsychiatric disorders. The initial clinical study is planned to start in Q2 2026.

The development of an oral KCC2 activator is significant because it is believed to have broad therapeutic and anti-psychotic activity, specifically mentioned in the context of psychosis linked to Parkinson's disease and Lewy body dementia.

The Q3 2025 net loss was $12.2 million, showing the investment required to bring these novel propositions to fruition.

Ovid Therapeutics Inc. (OVID) - Canvas Business Model: Customer Relationships

The engagement strategy for Ovid Therapeutics Inc. centers on specialized, high-value interactions across the scientific, patient, and financial communities, reflecting its focus on rare and complex brain conditions.

Direct engagement with Key Opinion Leaders (KOLs) in neurology and epilepsy.

Ovid Therapeutics Inc. actively involves world-leading experts to validate its scientific approach. For instance, Dr. Alexander Rotenberg, M.D., Ph.D., Professor of Neurology at Boston Children's Hospital and Harvard Medical School, joined a company event on June 12, 2025, to discuss the application of Biomarkers in Epilepsy, specifically relating to the OV329 clinical development program. The Phase 1 trial for OV329 enrolled 68 participants (51 receiving OV329 and 17 receiving placebo) to track target engagement using tools like magnetic resonance spectroscopy (MRS) and transcranial magnetic stimulation (TMS).

High-touch interaction with patient advocacy groups for rare disorders.

Ovid Therapeutics Inc. maintains a commitment to the epilepsy and cerebral cavernous malformation (CCM) communities, viewing patients and families as inspiration. The company fosters relationships with several key organizations:

• The Alliance to Cure Cavernous Malformation.
• EURORDIS-Rare Diseases Europe, an alliance of 869 rare disease patient organizations from 71 countries.
• The LGS Foundation.
• The Rare Epilepsy Network (REN).

The company notes that while it has limited financial resources for sponsorships or donations at this time, it is keen to explore options to provide volunteers or other resources to support these organizations.

Investor relations focused on communicating pipeline milestones and cash runway.

Investor relations activities in late 2025 were heavily focused on communicating significant clinical progress and recent capital raising efforts to secure the long-term operating plan. Ovid Therapeutics Inc. communicated the following key financial and pipeline data points:

Metric/Event	Value/Date
Cash, Cash Equivalents, Marketable Securities (as of September 30, 2025)	$25.6 million
Private Placement Gross Proceeds (October 2025)	Up to $175 million
Private Placement Initial Closing (October 2025)	Approximately $81 million
Extended Cash Runway (Post-Financing)	Into the second half of 2028
Cash Runway (Pre-Financing, as of March 31, 2025)	Into the 2H of 2026
Analyst Estimated Full-Year 2025 Sales	$6.69 million
Analyst Estimated Full-Year 2025 EPS	Loss of $0.47
Q3 2025 Net Loss Per Share	$0.17
Q3 2025 Royalty Revenue	$132,000

Pipeline milestones communicated to investors included the OV329 topline data readout in Q3 2025, results from the OV350 Phase 1 study in Q4 2025, initiation of a Phase 2a patient study for OV329 in Q1 2026, and initiation of a proof-of-concept trial for OV4071 in Q2 2026. The company also reported a $7.0 million royalty monetization agreement signed with Immedica Pharma AB for future ganaxolone royalties.

Collaborative relationships with academic research centers.

Ovid Therapeutics Inc. leverages formal alliances with academic and research institutions to advance its pipeline. The company has established several key collaborations:

• A strategic research collaboration with Columbia University Irving Medical Center began in June 2020.
• An exclusive, worldwide license agreement with Northwestern University was entered into in December 2016 for OV329.
• Continuing collaboration with Tufts Laboratory and Dr. Moss on the KCC2 compound library, which originated from an agreement with AstraZeneca.

Ovid Therapeutics Inc. (OVID) - Canvas Business Model: Channels

You're looking at how Ovid Therapeutics Inc. gets its value propositions out to the world, which, for a clinical-stage company, means regulatory milestones, scientific validation, and strategic partnerships. Here's the quick math on their channel activities as of late 2025.

Regulatory Submissions (INDs/CTAs) to the FDA and International Agencies

The primary channel here is the formal submission package that allows clinical trials to start. Ovid Therapeutics Inc. is actively engaging with regulators to move its pipeline forward.

• Ovid Therapeutics Inc. is in the process of seeking scientific advice with regulators across multiple regions regarding OV329.
• For OV4071, the first oral KCC2 direct activator, IND-enabling studies are completing, with plans to submit for regulatory clearance in Q1 2026.
• The anticipated initiation of a Phase 2a patient study for OV329 in drug-resistant epilepsies is set for Q1 2026.
• The potential initiation of a proof-of-concept trial for OV4071 is targeted for Q2 2026.

Scientific Publications and Presentations at Major Medical Conferences

Scientific validation through peer-reviewed data and conference presentations is a critical channel for establishing credibility and attracting partners. You see this activity spiking around data readouts.

• Ovid Therapeutics Inc. announced positive topline results from its Phase 1 study of OV329 on October 3, 2025.
• Topline results from the OV329 Phase 1 safety, tolerability and biomarker study were expected in Q3 2025.
• OV329 Phase 1 results were selected for a late-breaking poster presentation at the 2025 American Epilepsy Society (AES) annual meeting.
• Ovid Therapeutics Inc. hosted an investor and media event on June 12, 2025, focusing on biomarkers in epilepsy and the OV329 program.

Licensing and Collaboration Agreements with Pharmaceutical Partners

These agreements are dual-purpose channels: they validate the science and provide non-dilutive capital. The monetization of existing assets is a key part of the current funding strategy.

Ovid Therapeutics Inc. has several key arrangements that serve as channels for value realization:

Partner/Agreement Type	Key Financial/Status Detail	Date/Period
Immedica Pharma AB (Royalty Sale)	Sale of worldwide ganaxolone royalty rights for $7.0 million	June 2025
Royalty Agreements (Revenue)	Revenue of $6.3 million for Q2 2025	Q2 2025
Royalty Agreements (Revenue)	Revenue of $132,000 for Q3 2025	Q3 2025
Takeda (Soticlestat)	Upfront payment of $196.0 million received	Prior to 2025
Takeda (Soticlestat)	Eligible for up to an additional $660.0 million in milestones	Ongoing
Takeda (Soticlestat)	Tiered royalties up to 20 percent on net sales	If approved
Graviton (ROCK2 Inhibitors)	Collaboration and license agreement for development through Phase 2 trials	April 2023

Still, the company is actively advancing multiple oral and injectable KCC2 activator programs selected from its proprietary library, which sets the stage for future deals.

Investor Communications via SEC Filings and Earnings Calls

Transparency with the investment community is managed through required filings and scheduled calls. These communications channel financial health and pipeline progress directly to shareholders.

Here are some key figures from recent investor communications:

• Ovid Therapeutics Inc. announced a PIPE financing on October 3, 2025, for up to $175 million in gross proceeds.
• The initial closing of the PIPE financing was approximately $81 million.
• Shares of common stock outstanding as of August 8, 2025, were 71,109,514.
• Cash, cash equivalents and marketable securities totaled $38.3 million as of June 30, 2025.
• Cash, cash equivalents and marketable securities totaled $25.6 million as of September 30, 2025.
• The post-PIPE financing cash runway is expected to support operations into 2H 2028.
• The net loss for the third quarter ended September 30, 2025, was $12.2 million, or basic and diluted net loss per share of $0.17.
• SEC filings are current through November 12, 2025.

Finance: draft 13-week cash view by Friday.

Ovid Therapeutics Inc. (OVID) - Canvas Business Model: Customer Segments

You're looking at Ovid Therapeutics Inc. (OVID) as of late 2025, and the focus for customer acquisition is squarely on patients with significant, often refractory, central nervous system (CNS) conditions. The company's ability to pursue these segments is underpinned by recent capital, specifically the up to $175 million in gross proceeds from a Private Investment in Public Equity (PIPE) financing announced in October 2025, with an initial closing of approximately $81 million, which management stated extends the cash runway into the 2H 2028.

The primary patient groups Ovid Therapeutics Inc. is targeting are defined by the unmet need addressed by their pipeline assets, which modulate neuronal hyperexcitability.

• - Patients with drug-resistant focal onset seizures (DREs).
• - Patients with psychosis associated with Parkinson's disease and Lewy body dementia.
• - Patients with other neurological and neuropsychiatric conditions driven by neural hyperexcitability.
• - Pharmaceutical companies seeking novel CNS assets for regional rights.

For the drug-resistant epilepsies segment, Ovid Therapeutics Inc. is advancing OV329, a next-generation GABA-aminotransferase (GABA-AT) inhibitor. This patient group represents a substantial need, as an estimated 30% of epilepsy patients suffer from drug-resistant epilepsy. The focal seizures segment held the largest market share of 51% in the Epilepsy Drug Market in 2024. The company is planning the initiation of a Phase 2a patient study for OV329 in these drug-resistant epilepsies as early as Q1 2026 or Q2 2026.

The second major patient population centers around conditions driven by neuronal imbalance, specifically psychosis associated with Parkinson's disease and Lewy body dementia. This is being addressed via the KCC2 direct activator portfolio. Ovid Therapeutics Inc. projects the initiation of Phase 1b studies for OV4071, the oral KCC2 direct activator, in this indication around Q3 2026.

The broader category of other neurological and neuropsychiatric conditions is served by the entire KCC2 direct activator library, which aims to restore inhibitory tone in the brain. Key milestones here include the anticipated topline findings from the Phase 1 study of OV350 (Intravenous KCC2 Direct Activator) in Q4 2025. The company's focus on these CNS disorders is supported by recent asset monetization; for instance, a $7.0 million royalty monetization agreement for ganaxolone was signed with Immedica Pharma AB in June 2025.

The fourth segment involves other biopharma entities, which Ovid Therapeutics Inc. engages with for non-core asset monetization or potential regional rights deals. The royalty and licensing revenue for the nine months ended September 30, 2025, totaled $6.5 million, primarily stemming from an agreement with Takeda Pharmaceutical Company Limited. The company's market capitalization as of early October 2025 was approximately $116.62 million.

Here's a quick look at how the pipeline assets map to these customer-defining indications and the near-term data catalysts you should watch for:

Pipeline Asset	Mechanism/Class	Primary Target Customer Segment Indication	Key Near-Term Data Milestone (as of late 2025)
OV329	Next-generation GABA-AT inhibitor	Drug-resistant focal onset seizures (DREs)	Phase 1 results presented at AES 2025 meeting; Phase 2a initiation planned for Q1/Q2 2026.
OV350	KCC2 Direct Activator (IV)	CNS disorders driven by neuronal hyperexcitability	Phase 1 topline findings expected in Q4 2025.
OV4071	First-ever Oral KCC2 Direct Activator	Psychosis associated with Parkinson's/Lewy Body Dementia; other CNS disorders	First-in-human studies anticipated in Q2 2026; Phase 1b for psychosis projected for Q3 2026 start.

Ovid Therapeutics Inc. (OVID) - Canvas Business Model: Cost Structure

You're looking at the cost side of Ovid Therapeutics Inc. (OVID) as of late 2025, which is heavily weighted toward advancing its pipeline while managing a leaner operational footprint following prior restructuring. The primary cost drivers are the expenses tied directly to drug development and the overhead required to run a public, clinical-stage biopharma company.

The third quarter of 2025 (Q3 2025) financial results show a clear focus on R&D, though overall operating expenses were managed down year-over-year. Here's the quick math on the core operating costs for that quarter:

Cost Category	Q3 2025 Amount	Context/Driver
Research and Development (R&D) expenses	$5.9 million	Down from $7.9 million in Q3 2024, reflecting streamlined operations, including the pause of the OV888 (GV101) program.
General and Administrative (G&A) expenses	$6.8 million	Up from $5.5 million in Q3 2024, driven by specific non-routine costs.
Total Operating Expenses	$12.7 million	Down from $13.4 million in Q3 2024.

The structure of these costs reflects the company's current stage. You'll see that the G&A increase in Q3 2025, reaching $6.8 million, was specifically attributed to certain non-routine expenditures.

• Costs associated with maintaining and defending intellectual property: Ovid Therapeutics Inc. completed a strategic monetization of its ganaxolone asset in June 2025, selling worldwide royalty rights and licensing for $7.0 million. This deal included the transfer of the associated global ganaxolone intellectual property, with the buyer, Immedica Pharma AB, assuming responsibility for associated patent maintenance and prosecution costs. This move allowed Ovid Therapeutics Inc. to focus capital on its wholly owned pipeline and shed those specific IP upkeep expenses.
• Clinical trial costs and manufacturing of drug candidates: While specific Q3 2025 dollar amounts for clinical trial execution and drug candidate manufacturing aren't explicitly broken out separately from the R&D total of $5.9 million, the primary uses of capital are known to include third-party clinical research. The R&D spend supports active programs like the OV329 Phase 1 trial (with topline results in Q3 2025) and the OV350 Phase 1 study (results expected in Q4 2025).
• Compensation and professional fees, including non-routine business development fees: General and Administrative expenses primarily consist of employee-related costs, such as salaries, benefits, and stock-based compensation for executive and support functions. The increase in G&A to $6.8 million in Q3 2025 compared to the prior year was explicitly driven by non-routine business development professional fees. Other standard G&A costs include professional fees for auditing, tax, and legal services for operating as a public company.

Ovid Therapeutics Inc. (OVID) - Canvas Business Model: Revenue Streams

You're looking at how Ovid Therapeutics Inc. (OVID) is bringing in cash as of late 2025. For a company deep in clinical development, the revenue mix is often lumpy, relying on non-operational sources as much as product-adjacent income. Honestly, it's about bridging the gap until a wholly-owned asset gets across the finish line.

The core, recurring revenue stream is definitely tied to past deals. We saw royalty and licensing revenue totaling $6.5 million for the first nine months of 2025. That's a solid step up from the $0.5 million seen in the same nine-month period in 2024. To be fair, the third quarter itself was light on this front, bringing in only $0.1 million or $132,000 for the three months ending September 30, 2025. Still, that nine-month figure shows the importance of those existing agreements.

Ovid Therapeutics Inc. has also been strategic about monetizing non-core assets to bolster its balance sheet. The most recent, significant example was the sale of its future royalty rights for ganaxolone outside of China. This transaction, completed in June 2025, brought in proceeds of $7.0 million in cash from Immedica Pharma AB. This was a non-dilutive capital infusion, letting Ovid Therapeutics Inc. focus its internal capital on its wholly-owned pipeline, like OV329 and the KCC2 activators.

Here's a quick look at the key financial components feeding into the top line and capital structure as of late 2025:

Revenue/Financing Component	Amount/Value	Period/Date	Source Type
Royalty and Licensing Revenue (YTD)	$6.5 million	First nine months of 2025
Ganaxolone Royalty Sale Proceeds	$7.0 million	June 2025
Gross Proceeds from Private Placement	Up to $175 million	October 2025
Initial Gross Proceeds from Private Placement	Approximately $81 million	October 2025
Expected Cash Runway Funded Through	2028	Post-October 2025 Financing

Beyond operational revenue, the most impactful financial event for Ovid Therapeutics Inc.'s near-term runway was the equity financing. You saw the pricing of a Private Investment in Public Equity (PIPE) financing in October 2025, expected to bring in gross proceeds of up to $175 million. This deal was structured with an initial closing expected around October 6, 2025, yielding approximately $81 million before fees.

This capital infusion is defintely a game-changer for the business model, as it's intended to work alongside existing cash to fund the operating plan into 2028. This means Ovid Therapeutics Inc. has the financial backing to pursue key clinical catalysts without immediate pressure for further dilutive financing. The revenue streams, therefore, are a mix of:

• - Royalty and licensing revenue, totaling $6.5 million for the first nine months of 2025.
• - Upfront and milestone payments from strategic collaborations, which contribute to the overall licensing revenue.
• - Proceeds from the sale of non-core assets, like the $7.0 million ganaxolone royalty sale in June 2025.
• - Equity financing, including the October 2025 private placement of up to $175 million gross proceeds.